ZA202105833B - Arginase inhibitors and methods of use thereof - Google Patents

Arginase inhibitors and methods of use thereof

Info

Publication number
ZA202105833B
ZA202105833B ZA2021/05833A ZA202105833A ZA202105833B ZA 202105833 B ZA202105833 B ZA 202105833B ZA 2021/05833 A ZA2021/05833 A ZA 2021/05833A ZA 202105833 A ZA202105833 A ZA 202105833A ZA 202105833 B ZA202105833 B ZA 202105833B
Authority
ZA
South Africa
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
ZA2021/05833A
Other languages
English (en)
Inventor
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA202105833B publication Critical patent/ZA202105833B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2021/05833A 2019-02-08 2021-08-16 Arginase inhibitors and methods of use thereof ZA202105833B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
ZA202105833B true ZA202105833B (en) 2025-03-26

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/05833A ZA202105833B (en) 2019-02-08 2021-08-16 Arginase inhibitors and methods of use thereof

Country Status (33)

Country Link
US (2) US12435097B2 (https=)
EP (1) EP3921033B1 (https=)
JP (1) JP7526734B2 (https=)
KR (1) KR102759971B1 (https=)
CN (1) CN113395996B (https=)
AU (1) AU2020218651B2 (https=)
BR (1) BR112021015581A2 (https=)
CA (1) CA3127755A1 (https=)
CL (1) CL2021002056A1 (https=)
CO (1) CO2021011039A2 (https=)
CR (1) CR20210463A (https=)
DK (1) DK3921033T3 (https=)
DO (2) DOP2021000166A (https=)
EA (1) EA202192114A1 (https=)
ES (1) ES2960034T3 (https=)
FI (1) FI3921033T3 (https=)
HR (1) HRP20231092T1 (https=)
HU (1) HUE062968T2 (https=)
IL (1) IL285108B2 (https=)
LT (1) LT3921033T (https=)
MA (1) MA56324B1 (https=)
MX (1) MX2021009499A (https=)
MY (1) MY206577A (https=)
PE (1) PE20220280A1 (https=)
PH (1) PH12021551902A1 (https=)
PL (1) PL3921033T3 (https=)
PT (1) PT3921033T (https=)
RS (1) RS64781B1 (https=)
SG (1) SG11202108503PA (https=)
SI (1) SI3921033T1 (https=)
SM (1) SMT202300337T1 (https=)
WO (1) WO2020161675A1 (https=)
ZA (1) ZA202105833B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) * 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2018138195A (ru) * 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN108794517B (zh) 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) * 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DOP2024000181A (es) 2024-10-15
BR112021015581A2 (pt) 2021-10-05
CN113395996A (zh) 2021-09-14
HUE062968T2 (hu) 2023-12-28
EP3921033A1 (en) 2021-12-15
CO2021011039A2 (es) 2021-09-09
SMT202300337T1 (it) 2023-11-13
JP7526734B2 (ja) 2024-08-01
PT3921033T (pt) 2023-10-11
US20250282800A1 (en) 2025-09-11
IL285108A (en) 2021-09-30
KR102759971B1 (ko) 2025-01-23
MA56324B1 (fr) 2023-10-31
IL285108B1 (en) 2024-06-01
FI3921033T3 (fi) 2023-09-15
PL3921033T3 (pl) 2024-01-15
DK3921033T3 (da) 2023-10-16
DOP2021000166A (es) 2021-09-30
MX2021009499A (es) 2021-09-08
JP2022521474A (ja) 2022-04-08
PE20220280A1 (es) 2022-02-25
SI3921033T1 (sl) 2023-11-30
IL285108B2 (en) 2024-10-01
CR20210463A (es) 2021-10-15
SG11202108503PA (en) 2021-09-29
WO2020161675A1 (en) 2020-08-13
ES2960034T3 (es) 2024-02-29
RS64781B1 (sr) 2023-11-30
CL2021002056A1 (es) 2022-03-04
KR20210126044A (ko) 2021-10-19
PH12021551902A1 (en) 2022-08-01
US12435097B2 (en) 2025-10-07
AU2020218651B2 (en) 2023-01-12
US20220106335A1 (en) 2022-04-07
LT3921033T (lt) 2023-09-25
CA3127755A1 (en) 2020-08-13
EA202192114A1 (ru) 2021-12-01
EP3921033B1 (en) 2023-07-26
AU2020218651A1 (en) 2021-09-30
CN113395996B (zh) 2024-05-28
MY206577A (en) 2024-12-24
HRP20231092T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
SG11202107614PA (en) Pcsk9 inhibitors and methods of use thereof
ZA202407941B (en) Arginase inhibitors and methods of use thereof
SG11202107615TA (en) Pcsk9 inhibitors and methods of use thereof
SG11202111327XA (en) Fgfr inhibitors and methods of use thereof
IL287973A (en) acss2 inhibitors and methods of their use
SG11202105769XA (en) Inhibitors of apol1 and methods of using same
IL287751A (en) Kcnt1 inhibitors and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
IL280924A (en) Arginase inhibitors and methods of using them
IL289649A (en) Formulations of rbp4 inhibitors and methods of use
IL264854A (en) Spt5 inhibitors and methods of use thereof
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
IL326879A (en) EGFR allosteric inhibitors and methods of using them
ZA202105833B (en) Arginase inhibitors and methods of use thereof
IL286149A (en) Caspase inhibitors and methods of using them
HK40075179A (en) Arginase inhibitors and methods of use thereof
HK40064703A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40063536A (en) Acss2 inhibitors and methods of use thereof
HK40062239A (en) Acss2 inhibitors and methods of use thereof
HK40069053A (en) Kcnt1 inhibitors and methods of use
HK40064385A (en) Pcsk9 inhibitors and methods of use thereof
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof